

**REMARKS**

Restriction to one of the following groups was required under 35 USC 121:

- Group I        Claims 1-5, 14, 15 drawn to method for reducing inflammation by LXR agonist, classified in class 514, in general.
- Group II.      Claims 8-10, drawn to method for reducing inflammation by LXR agonist and NSAID, classified in class 514, in general. Claims 6, 7 are linking claims.
- Group III.     Claims 12, 13, drawn to method for reducing inflammation by LXR agonist and corticosteroid, classified in class 514, in general. Claims 6, 7 are linking claims.
- Group IV      Claims 16, 17, drawn to method for inhibiting gene expression, classified in class 536, subclass 24.5
- Group V       Claims 18, 19, drawn to method for identifying anti-inflammatory compounds, classified in class 435, subclass 7.1.
- Group VI      Claim 20, drawn to pharmaceutical composition, which are only classifiable upon selection of an ultimate compound species.

In response to this restriction requirement, Applicant elects Group I, that is claims 1-5, 14 and 15.

*Election of species*

Additionally, an election of species was required for claim 4 (in the elected group I) – type of effect of treatment, selected from i) treating, ii) controlling, iii) preventing or reducing risk of contacting disease.

In response to this restriction requirement, Applicant elects species i) treating, with the understanding that upon allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. Currently, Claim 4 is generic.

**Application No.:** 10/755,720  
**Filing Date.:** January 12, 2004

### CONCLUSION

In view of the foregoing, Applicant respectfully requests that this application be passed to issuance. In any point remains that can be resolved by telephone, the Examiner is invited to contact the undersigned at the below-given telephone number.


Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: October 25, 2007

By: \_\_\_\_\_

  
Marina I. Gordey  
Registration No. 52,950  
Agent of Record  
Customer No. 20995  
(805) 547-5580

AMEND

4445799  
102307